24
Is there a place for Ulipristal Acetate in adenomyosis medical treatment? J. Ferreri, M. Gràcia, I. Vives, M.J. Mar2nezSerrano, F. Carmona Ins:tut Clínic de Ginecologia, Obstetrícia i Neonatologia Hospital Clínic de Barcelona, Spain

Isthere#aplace#for#Ulipristal Acetate#in#adenomyosis…seud.org/wp-content/uploads/2016/05/5.Ferreri-Is-there-a... · 2016-05-23 · Adenomyosis#and#symptomac #fibroids# Global#self5rated#clinical#symptoms#

Embed Size (px)

Citation preview

Is  there  a  place  for  Ulipristal  Acetate  in  adenomyosis  medical  

treatment?  J.  Ferreri,  M.  Gràcia,  I.  Vives,  M.J.  Mar2nez-­‐Serrano,  F.  Carmona  

Ins:tut  Clínic  de  Ginecologia,  Obstetrícia  i  Neonatologia  Hospital  Clínic  de  Barcelona,  Spain  

Ulipristal  Acetate  

           Modulates  conforma:onal  changes  SPRM  

Gene    transcrip:on  

Gene      down-­‐regula:on  

PR   PR  

PR   PR  

Co-­‐ac:vator  

Co-­‐repressor  

Ulipristal  

Ulipristal  Acetate  

Selec:ve  Progesterone  Receptor  Modulator  (SPRM)  An:-­‐prolifera:ve  and  apoptosis  induc:on  Chronic  intermiPent  treatment  Symptoma:c  fibroids:      Preopera:ve  treatment      AUB-­‐L  control  

Ulipristal  Acetate  

Ulipristal  acetate  

An:-­‐prolifera:ve  effect  

Bleeding  control  

Ectopic  endomytrium  

:ssue  

AUB-­‐  A  Pelvic  pain  

Adenomyosis  

Objec9ve  

To  evaluate  the  effect  of  Ulipristal  Acetate  on  adenomyosis  in  pa:ents  

with  synchronic  fibroids  

Ultrasound  criteria  

Adenomyosis  and  symptoma:c  fibroids  

Global  self-­‐rated  clinical  symptoms  UFQ-­‐Qol  with  emphasis  on  symptoms  severity  

Biggest  fibroid  volume  Uterine  volume  

Clinical  assessment  

Ulipristal  acetate  

Study  design  

Haemoglobin  concentra:on  

Clinical  assessment  

Results  

Baseline  Characteris9cs    

Adenomyosis  and  Fibroids     Fibroids  

Age  (years)  Mean  (SD)   44,5  (5,3)   43,5  (6,0)  

BMI  (Kg/m2)  Mean  (SD)  

25,9  (3,4)     24,2  (4,3)  

AUB     14/14  (100%)   49/52  (94,2%)  

Pelvic  pain   5/14  (35,7%)   8/52  (15,3%)  

Clinical  Results    

   Hb  concentra9on  

 UFQ-­‐Qol  Symptoms  severity  

Adenomyosis  and  fibroids  

Biggest  fibroid  difference  (cc)   -­‐27,5  

Uterine  volume  difference  (cc)   -­‐12,0  

US  findings  

Fibroids complicated by adenomyosis

Conclusion  

Fibroids   Adenomyosis  

Alterna9ve  treatment  for  pa9ents  suffering  from  adenomyosis  alone?  

 Further  studies  are  required  

Bicêtre Hospital, France Hervé FERNANDEZ, MD, PhD

PAEC  

Progesterone  Receptor  Modulator  Associated  Endometrial  Changes  Inac:ve  epithelium  with  stromal  growth  and  glandular  cys:c  dilata:on